FILING ANALYSIS · TUESDAY, NOVEMBER 10
ATOSSA THERAPEUTICS, INC. ATOS — 8-K: Results of Operations and Financial Condition
neutral
Atossa Therapeutics reported its third quarter 2026 financial results and provided a corporate update, including a contingent value rights agreement that entitles holders to share in 25% of the net proceeds from the sale of the first priority review voucher awarded to Atossa, with no quantified surprise or significant news that would impact the stock price beyond 1.5% in a week
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →